Meeting
2015 ASCO Annual Meeting
A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC).
Authors
Sara M. Tolaney
Dana Farber Cancer Institute, Boston, MA
Sara M. Tolaney , David R. Ziehr , Hao Guo , William Thomas Barry , Michaela Jane Higgins , Steven J. Isakoff , Jane E. Brock , Elena Ivanova , Cloud Paweletz , Michelle Demeo , Nikhil H. Ramaiya , Beth Overmoyer , Rakesh K. Jain , Dan G. Duda , Eric P. Winer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT02260531
Citation
J Clin Oncol 33, 2015 (suppl; abstr 1080)
DOI
10.1200/jco.2015.33.15_suppl.1080
Abstract #
1080
Poster Bd #
194
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC).
First Author: Dan G. Duda
Poster
2013 ASCO Annual Meeting
TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC).
First Author: Christos Vaklavas
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2023 ASCO Annual Meeting
The ARETHA study: A phase 2 randomized control trial of eribulin with evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer (TNBC) and metabolic dysfunction.
First Author: Sherry Shen